GGrantIndex
Sort

30,917 grants matching tumor microenvironment

NOX family NADPH oxidases: roles in innate immunity and inflammatory disease

$761,504
Thomas Leto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Quantitative imaging phenotypic classifier for distinguishing radiation effects from tumor recurrence in Glioblastoma

$761,344
Pallavi Tiwari · University Of Wisconsin-Madison · R01 · FY2023 · CA

Southwest Early Clinical Trials - Phase 2 Consortium

$759,923
Funda Meric-Bernstam · University Of Tx Md Anderson Can Ctr · UM1 · FY2016 · CA

Novel Markers for Disease Outcome in Breast Cancer

$759,873
Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients

$759,496
Cecilia Larocca · Brigham And Women'S Hospital · R37 · FY2020 · CA

Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors

$759,285
James F Kronauge · Cytosite Biopharma, Inc. · R44 · FY2019 · CA

Development of TGF-beta antagonists for cancer therapy

$758,999
Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy

$758,985
Siddharth Balachandran · Research Inst Of Fox Chase Can Ctr · R01 · FY2023 · CA

Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy

$758,985
Siddharth Balachandran · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA

Coordinating and Data Management Center for Acquired Resistance to Therapy Network

$758,183
Alan David Hutson · Roswell Park Cancer Institute Corp · U24 · FY2024 · CA

Role of the microenvironment in regulating early stages of thymic involution and central tolerance

$757,731
Lauren Ilyse Richie Ehrlich · University Of Arizona · P01 · FY2024 · AG

Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology

$757,626
Wendy S. Garrett · Harvard University D/B/A Harvard School Of Public Health · R01 · FY2025 · CA

The Molecular Profile of Prostate Tumors in African-American Men

$757,524
Stefan Ambs · Basic Sciences · Z01 · FY2007 · CA

Fibroblast Heterogeneity in Pancreatic Cancer

$756,549
David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2024 · CA

New approach for immune modulation against T1D

$756,491
Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2024 · DK

Biostatistics Core

$756,209
Peter A Jones · University Of Southern California · P30 · FY2014 · CA

ECM geometrical and mechanical properties modulate RTK signaling

$756,191
Jay T. Groves · University Of California Berkeley · U01 · FY2017 · CA

Zebrafish core

$756,150
Christine Kettenhofen · Division Of Basic Sciences - Nci · ZIC · FY2023 · CA

Biostatistics Core

$755,906
Peter A Jones · University Of Southern California · P30 · FY2015 · CA

Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response

$755,852
Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Zebrafish core

$755,762
Christine Kettenhofen · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA

CLINICAL THERAPY TRIALS

$755,312
Katherine Kurshan Matthay · Children'S Hospital Of Los Angeles · P01 · FY2009 · CA

Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell Carcinoma

$754,861
Nicole Schmitt · National Institute On Deafness And Other Communication Disorders · ZIA · FY2016 · DC

Targeting Stoma-Tumor Co-Dependency for Glioma Therapy

$754,845
David H. Gutmann · Washington University · U01 · FY2012 · CA

Hydrogel microparticle technology for high-throughout screening of chimeric antigen receptor-T cells based on single cell effector function

$754,792
Joseph De Rutte · Partillion Bioscience Corporation · R44 · FY2023 · GM